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Introduction
The human mammaglobin (h-MAM) gene was recently
cloned by Watson and colleagues [1]. It maps to chromo-
some 11q12-13, and the amino acid sequence it encodes
is similar to that of epithelial secretory proteins belonging
to the uteroglobin family, all of which are encoded by
genes clustered on the same chromosomal region [2].
Mammaglobin expression has been observed in breast
epithelial cells, but not in myoepithelial or stromal breast
cells [3]. Zach and colleagues [4] were not able to detect
mammaglobin expression by means of reverse transcrip-
tase–polymerase chain reaction (RT–PCR) in the human
uterus, ovary or leukocytes [4]. However, Grünewald and
colleagues [5], using the same technique, have shown
mammaglobin to be expressed in normal and malignant
tissues from the ovary, uterus and cervix, as well as in both
prostatic hyperplasia and cancer. In a previous paper, the
same authors had used mammaglobin experimentally to
bp = base pairs; RT–PCR = reverse transcriptase–polymerase chain reaction.
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Abstract
Background: Mammaglobin (h-MAM) is expressed mainly by
breast epithelial cells, and this feature has been used to detect
circulating breast cancer cells and occult metastases in
sentinel axillary lymph nodes of breast cancer patients.
However, the biological role of mammaglobin is completely
unknown.
Methods: We studied 128 fresh-frozen breast cancer
specimens by means of reverse transcriptase–polymerase
chain reaction and quantified their h-MAM mRNA expression.
This was then correlated with histological and nuclear grade,
oestrogen and progesterone receptor expression, c-erb-B2
and mutant p53 expression, as well as with cellular proliferation
measured by means of the Ki67 labelling index, DNA ploidy
and S-phase, and finally with the presence or not of invaded
axillary nodes in the mastectomy specimen.
Results: In the univariate analysis, high h-MAM expression
(above the median for the whole group) correlated significantly
(P<0.05) with oestrogen and progesterone receptor
expression, diploid DNA content, low Ki67 labelling index, low
nuclear grade and almost significantly (P=0.058) with the
absence of axillary nodal invasion in the mastectomy specimen.
In a final, multivariate model, only progesterone receptor
expression, diploid DNA content and absence of nodal invasion
were found to be independently associated with high h-MAM
expression.
Conclusion: All of the features associated with mammaglobin
expression reflect, without exception, a less aggressive tumour
phenotype. Further studies are needed to clarify whether this is
attributable to h-MAM expression itself, or to another
mechanism of which mammaglobin expression forms part.
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detect circulating breast cancer cells, showing by means
of RT–PCR a sensitivity threshold of one tumour cell per
million mononuclear blood cells [6]. Mammaglobin has
also been used for detecting occult metastases in sentinel
axillary lymph nodes of breast cancer patients by means of
RT–PCR [7].
However, the biological role of mammaglobin in breast
tissue, and by extension in breast cancer, is completely
unknown. The biologically active form seems to be a
complex formed between mammaglobin and another
member of the family, BU101, also known as lipophilin B
[8], so its mechanism of action might form part of a more
complicated chain involving several elements.
In the present study we have quantified the expression of
mammaglobin in a series of human breast carcinomas,
and have correlated this expression with all available clini-
cal and molecular parameters, with the intent of clarifying
its biological role in breast cancer.
Materials and methods
The tumours were obtained from patients operated on for
breast cancer at Fundación Tejerina, Madrid, Spain, after
having obtained written informed consent for doing so
before surgery. The tumour fraction was identified at the
time of intraoperative biopsy (which was performed in all
patients), to exclude, to any possible extent, contamination
from normal breast tissue. The specimens were either
immediately snap-frozen in liquid N2, or immersed in
RNAlater™ (Ambion Inc, Austin, Texas, USA) and frozen at
–80°C over the next 24 hours.
In all, 128 tumour specimens were studied, of which 104
were infiltrating ductal carcinomas (IDC), 20 were lobular
infiltrating carcinomas (LIC) and 4 were tubular carcino-
mas. These fresh tumour specimens were used for the
extraction of RNA and RT–PCR and also for flow cytome-
try. The immunohistochemical procedures described
below, in their turn, were performed on slides from rou-
tinely processed paraffin blocks used for conventional
pathological examination.
Of the 128 patients, 15 had received chemotherapeutic
treatment, and the tumour specimen was obtained at the
time of rescue mastectomy. The rest had received no
treatment whatsoever.
RT–PCR
RNA was extracted from the tumour specimens with the
RNeasy™ commercial kit (Ambion Inc), in accordance with
the manufacturer’s instructions. The total RNA content
was immediately quantified in a spectrophotometer
(GeneQuant pro RNA/DNA calculator®; Amersham Phar-
macia Biotech, Uppsala, Sweden) after dilution 1:10 in
RNase-free water, and the RNA was then frozen at –80°C
until further use. The RT–PCR reaction was performed in
a thermal cycler with a commercial one-step RT–PCR kit
(Ambion Inc). The primers used were 5′-GAA GTT GCT
GAT GGT CCT CAT GCT GGC-3′ (sense) and 5′-CTC
ACC ATA CCC TGC AGT TCT GTG AGC-3′ (antisense),
and the conditions of RT–PCR were as follows: denatur-
ing, 95°C for 30s; annealing, 62°C for 15s; elongation,
72°C for 20s (30 cycles); and final cycle, 72°C for 7 min.
The primers encompass the whole open reading frame of
the h-MAM gene, which is made possible by the relatively
small size of the three exons forming it (44, 189 and 36
base pairs [bp], respectively). Furthermore, the presence
of two comparatively large introns between them (604 and
1890 bp, respectively), avoids the appearance of false
positive bands caused by co-amplification of contaminat-
ing DNA.
The β-globin gene was co-retrotranscribed and amplified
in parallel under exactly the same conditions in a second
tube as part of each reaction, using a set of extremely per-
missive primers and the same amount of mRNA, to func-
tion as an internal positive control (Fig.1). Because 1µl of
the extracted RNA solution was used directly for RT–PCR,
without further dilution, to obtain a homogeneous RNA
concentration in all the samples, the band pairs in the
different lanes of the gel shown in Fig.1 have different
intensities, reflecting the original RNA concentration
corresponding to each tumour studied.
After amplification, 10µl of each product was run for
20 min in a 2% agarose gel at 100 V, which was then
stained with ethidium bromide. The bands were detected
in a ultraviolet transilluminator, photographed with a Kodak
Digital Science DC-40™ digital camera and analysed by
means of the 1D Image Analysis Software™ package, both
from Eastman Kodak (Rochester, NY, USA). By means of
the latter, we measured the net density of the bands.
Dividing this by the net intensity of the control band (‘dif-
ferential PCR’), or by the initial RNA concentration of the
sample, we obtained a measurement in arbitrary units that
reflects, in comparison with that of the remaining samples,
Figure 1
Reverse transcriptase–polymerase chain reaction (RT–PCR) analysis
of mammaglobin expression in human breast cancer. N=128.
Lanes 1–6, mammaglobin RT–PCR product (269 base pairs [bp])
above, β-globin internal control below; lane 7, 100bp ladder.
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the relative expression of the gene under study in each of
them. Both values were closely correlated with each other
(r=0.4537,  P<0.0001) and were interchangeable for
comparative purposes. Thus, after having processed one-
third of the samples, and realising that we always obtained
a measurable h-MAM band, we decided to abandon the
co-amplification of the β-globin gene and just used the
relationship between the source RNA concentration and
the final band density for quantifying h-MAM expression,
which halved our expenses on RT–PCR reagents.
Immunohistochemistry
The immunohistochemical technique employed was the
standard one at our laboratory, and has been described
extensively elsewhere [9]. In brief, 5µm paraffin sections
were mounted on poly-L-lysine coated slides for heat-
induced epitope retrieval (‘HIER’ technique) in citrate
buffer. We used the same commercially available strepta-
vidin–biotin–peroxidase kit (Histostain-SP; Zymed, San
Francisco, California, USA) throughout the whole proce-
dure, to ensure uniformity of results. The antibodies
employed were as follows: NCL-CB11 (c-erb-B2), NCL-
ER-6F11 (oestrogen receptor) and NCL-p53-D07 (p53),
all from Novocastra Laboratories (Newcastle, UK); and
prediluted MIB1 (Ki67) and PR-2C5 (progesterone recep-
tor) from Zymed. The incubation time was 1h at room tem-
perature in a humid chamber for all antibodies, which,
apart from the prediluted MIB1-Ki67 solution (which was
directly used as supplied), were employed at the following
dilutions: NCL-CB11 (c-erb-B2), 1:40; NCL-ER-6F11
(oestrogen receptor), 1:100; NCL-p53-D07, 1:100. The
evaluation of nuclear staining patterns (oestrogen recep-
tor, progesterone receptor, Ki67 and p53) was straightfor-
ward, because tumours positive for oestrogen receptor,
progesterone receptor or p53 always showed specific
staining in more than 10% of tumour cells. For p53, this
tends to reflect adequately the expression of mutant p53
protein, as we have shown in the past by comparing p53
immunostaining and the detection of point mutations by
means of single-strand conformation polymorphism [10].
In a later study [11], Schmitt and colleagues showed that
tumours with less than one-third of the cells only moder-
ately staining on immunohistochemistry had no detectable
mutation of the p53 gene. If this more stringent criterion
was applied to the tumours of our study, only 3 of the 21
with positive staining for p53 did so in less than one-third
of the cells (one of them, however, very strongly in 20% of
cells). Reassignment of the two cases with moderate
staining in less than one-third of the cells, according to
Schmitt and colleagues, would not alter the general
results (see Table 2), so we adhered to our standard cut-
off of 10% throughout the study. The Ki67 labelling index
was expressed as the percentage of reactive tumour cells.
The tumours were considered to be positive for c-erb-B2
when more than 10% of cells showed complete specific
membrane staining.
Flow cytometry
Fresh tumour tissue, kept in phosphate-buffered saline at
4°C until processing (not more than 24 hours later), was
finely minced with a scalpel blade, mixed with 2ml of
DNA-prep Stain reactant and 100µl of DNA-prep LPR
reactant (both from Coulter Corporation, Miami, Florida,
USA), and incubated for 30 min at 37°C. The resulting
mixture was then filtered through a 50µm pore filter and
was then ready for cytometric analysis in a Coulter EPICS
XL cytometer (Coulter Corporation). Analysis of the his-
tograms obtained was performed with the help of the Mul-
tiCycle DNA Cell Cycle Analysis software package
(Phoenix Flow Systems, San Diego, California, USA).
Tumours were considered diploid when the DNA index
obtained was 1.0, and aneuploid for any value diverging
from 1.0, including tetraploid tumours, with a DNA index of
2.0.
Statistics
For comparative purposes with all other qualitative vari-
ables, the h-MAM expression values, expressed in arbi-
trary units, were split into ‘high’ and ‘low’, using for this
purpose the median value for the whole group (205.78
units) as a cut-off. All clinical and biological tumour vari-
ables potentially associated with high h-MAM expression
were individually tested in a univariate model (Table 1).
Those associations attaining or showing a trend towards
statistical significance were subsequently included in a
multivariate model (Table 2), in which high h-MAM expres-
sion was taken as the dependent variable. This was done
with the purpose of identifying clinical or biological fea-
tures independently associated with h-MAM expression,
because many of the parameters tested in the tumours are
known to be closely interrelated (for example, DNA ploidy
and Ki67 labelling index). The statistical analysis was per-
formed with the STATA statistical package (Stata Corpo-
ration, College Station, Texas, USA).
Results
RNA was obtained from all 128 tumour specimens, and
the h-MAM c-DNA was successfully retrotranscribed and
amplified in all cases.
The expression level, quantified in arbitrary units as
described above, ranged from 3.4 to 920.4 units.
From the univariate model, it can be seen that ‘high’
h-MAM expression was correlated significantly with
oestrogen receptor and progesterone receptor expres-
sion, diploid DNA content, low Ki67 labelling index and
low nuclear grade, and almost significantly with absence
of axillary nodal invasion in the mastectomy specimen. All
these features, without exception, reflect a less aggressive
tumour phenotype. There was no difference in h-MAM
expression between tumours from previously treated and
untreated patients (Table 1), or between tumours belong-
Available online http://breast-cancer-research.com/content/5/3/R65ing to different histological varieties of breast cancer. Elim-
inating the 15 previously treated patients from the analysis
altered the results only slightly in the multivariate analysis,
in which progesterone receptor expression and the
absence of nodal invasion was independently associated
with high h-MAM expression in untreated patients; in con-
trast, if the whole group was considered, diploid DNA
content and progesterone receptor expression retained
statistical significance. However, as can clearly be seen
from Table 2, the general trend is maintained throughout,
whether or not previously treated patients are included in
the analysis.
Discussion
Watson and Fleming [3] were the first to study mamma-
globin expression by means of RT–PCR and Northern
blotting in human breast cancer specimens. They studied
35 breast carcinomas of different histological varieties,
and found h-MAM to be overexpressed (at least 10-fold
relative to normal breast tissue) in 23% of cases. This cor-
responds roughly to the 75th centile of our distribution
expressed in arbitrary units, so both findings are superim-
posable. Ours also agree with those of Watson and col-
leagues in that mammaglobin expression is not bound to
any particular histological variety of breast cancer. Again,
Watson and colleagues studied the expression of mam-
maglobin in breast cancer by means of immunohistochem-
istry [10], and found a high immunoreactivity in 81% of
tumours. There were once more no differences according
to histological variety. Moreover, they detected mamma-
globin mRNA by means of RT–PCR in 10 of 11 lymph
nodes from patients with metastatic breast cancer, reflect-
ing their colonisation by cells from the primary tumour.
This specificity of mammaglobin for breast epithelial cells
has been widely used to detect circulating metastatic cells
in the blood of breast cancer patients [4,6]. However, to
our knowledge, mammaglobin expression has not previ-
ously been correlated with other clinical and biological
features of the tumours, as we have done, to achieve a
better understanding of its role in the oncogenic activation
of breast ductal and lobular epithelial cells. Our results, in
this sense, all point towards the same conclusion: that a
high h-MAM expression reflects a better differentiation, a
lower proliferation rate and a higher hormone dependence
of the tumours, all of which together define a better prog-
nosis. This is corroborated by the fact that we also found
in our series a significant inverse correlation between a
high mammaglobin expression and the most important
negative clinical prognostic factor for breast cancer,
namely axillary nodal invasion.
There still remains the open question of whether this is
attributable to a particular mechanism mediated by mam-
maglobin, or whether mammaglobin expression is just a
feature of the normal breast epithelial cell that gets lost
during the dedifferentiation process associated with
increasing malignant transformation. However, it seems
that things might not be as simple as that. Watson and
Fleming [3] reported that h-MAM mRNA levels tend to be
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Table 1
Univariate analysis of the relationship between mammaglobin
expression and all studied clinical and biological variables
Mammaglobin
Variable n > 205.78a (%) OR 95% CI P
Histology
Ductal + tubular 108 52 (48) 1.00
Lobular 20 12 (60) 1.62 0.61–4.30 0.332
Chemotherapy
No 15 55 (49) 1.00
Yes 128 9 (60) 1.58 0.52–4.77 0.412
Histological grade
1+2 60 32 (53) 1.00
3 42 17 (40) 0.60 0.27–1.34 0.203
Nuclear grade
1+2 52 30 (58) 1.00
3 51 19 (37) 0.44 0.19–0.98 0.039
Nodal metastasis
No 70 40 (57) 1.00
Yes 55 22 (40) 0.50 0.24–1.04 0.058
DNA ploidy
>1 68 27 (40) 1.00
1 60 37 (62) 2.44 1.17–5.08 0.014
Oestrogen receptor
Negative 34 12 (35) 1.00
Positive 93 52 (56) 2.33 1.01–5.34 0.040
Progesterone receptor
Negative 62 23 (37) 1.00
Positive 66 41 (62) 2.78 1.32–5.84 0.005
c-erbB-2
Negative 103 53 (51) 1.00
Positive 25 11 (44) 0.74 0.31–1.79 0.505
p53
Negative 107 56 (52) 1.00
Positive 21 8 (38) 0.56 0.21–1.48 0.235
Ki67
≤20% 79 46 (58) 1.00
>20% 49 18 (37) 0.42 0.20–0.88 0.019
CI, confidence interval; OR, odds ratio. aMedian for the whole group of
patients.higher in tumours than in the corresponding normal breast
tissue, something we also found in the course of our
investigation. In fact, of the 45 normal tissues from the
operated breasts containing the studied tumours available
to us, 29 (64.4%) showed lower mammaglobin expression
levels than those of the corresponding tumours, whereas
the contrary was true of the remaining 16 normal tissues.
However, we are reluctant to derive any conclusions from
these findings because of the small sample size, on the
one hand, and the doubts about how normal is ‘normal’
breast tissue from a breast in which cancer has already
arisen, on the other. In fact, this fundamental question is
the main subject of our continuing investigation.
Finally, the possibility remains that mammaglobin expres-
sion might be hormonally regulated, and that all other fea-
tures associated with a less aggressive phenotype might
be a by-product of hormonal activity. In favour of this
hypothesis stands our finding of a significant association
between high h-MAM levels and hormone receptor
expression in the studied tumours, and a previous report
by Zach and colleagues [4], who found elevated circulat-
ing levels of h-MAM mRNA to be significantly associated
with the presence of tumours positive for oestrogen
receptor.
Conclusion
In conclusion, high mammaglobin expression in breast
cancer is associated with a significantly less aggressive
tumour phenotype. Further studies are needed to clarify
whether this is attributable to h-MAM expression itself or
to another mechanism of which mammaglobin expression
forms part.
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